About Epic Sciences
Epic Sciences is a Healthcare company based in San Diego (United States) founded in 2008. Non-invasive tests for detecting circulating tumor cells are provided. Epic Sciences has raised $204.5 million across 7 funding rounds from investors including LabCorp, Roche and ARE. The company has 98 employees. Its website epicsciences.com draws about 35 thousand monthly visits. Epic Sciences offers products and services including AR-V7 Test and Biopharma Solutions. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is EPIC SCIENCES, INC. Its competitors include Guardant Health, GRAIL and Foundation Medicine; 3 of its 3 listed competitors have raised funding.
Company details
Provider of non-invasive tests for the detection of circulating tumor cells. The proprietary platform uses specialized assays and advanced digital pathology algorithms to identify circulating tumor cells from whole blood. The flagship product is Epic AR-V7 which detects the presence of AR-V7 biomarker in whole blood and associates it with the response rate for treatment with Zytiga and Xtandi. The first proposed application is metastatic castration-resistant prostate cancer.
- Headquarters San Diego, United States
- Employees 98
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website epicsciences.com
- Social LinkedIn X
- Legal Name Epic Sciences, Inc.
- Total Equity Funding$204.5M (USD)
in 7 rounds
- Latest Funding Round$24M (USD), Series G
Apr 2023
- InvestorsLabCorp
& 17 more
- Employee Count98
Products & Services of Epic Sciences
Epic Sciences offers a comprehensive portfolio of products and services, including AR-V7 Test and Biopharma Solutions.
Liquid biopsy test for prostate cancer therapy selection.
Platform for cancer research and drug development insights.
Funding Insights of Epic Sciences
Epic Sciences has successfully raised a total of $204.5M across 7 strategic funding rounds. The most recent funding activity was a Series G round of $24 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $204.5M
- Total Rounds 7
- Last Round Series G — $24M
- First Round $2.5M
(Jun 2009)
- Investors Count 18
All 7 funding rounds of Epic Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2023 | $24M | Series G | – | Deerfield, Arsenal Capital Partners | |
| Jun 2022 | $43M | Series F | – | Arsenal Capital Partners | |
| Sep 2018 | $52M | Series E | – | Blue Ox Healthcare Partners | |
| Apr 2017 | $40M | Series D | – | Hermed Capital | |
| Jul 2014 | $30M | Series C | – | RusnanoMedInvest, Arcus Ventures | |
| Nov 2012 | $13M | Series B | – | Domain Associates, Roche | – |
| Jun 2009 | $2.5M | Series A | – | Venrock | – |
18 investors in total: 18 institutional.
Investors in Epic Sciences
Epic Sciences has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include LabCorp, Roche and ARE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Private equity investments target specialty industrials and healthcare sectors. | 2000 | arsenalcapital.com | New York, United States | |
Commercial-ready healthcare innovators are targeted for private equity investments. | 2009 | blueoxhcp.com | New York, United States | |
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
| altos-capital.com | ||||
| vi-ventures.com | ||||
| hermedcapital.com | ||||
| pagodainv.com | ||||
| rmivc.com | ||||
Healthcare investments are managed by corporate-backed venture capital fund RusnanoMedInvest. | rmi.com.ru | Moscow, Russia |
Investor details for Epic Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Epic Sciences
13 people are tracked at Epic Sciences (7 in leadership, 6 in board & advisors); the tracked headcount is 98.
| Name | Role | Group |
|---|---|---|
Richard J. Wenstrup | Chief Medical Officer | Leadership |
Mark Aguillard | Chief Commercial Officer | Leadership |
Lloyd Sanders | President & CEO | Leadership |
Martin Blankfard | VP, Strategic Initiatives | Leadership |
Jason Christiansen | CTO | Leadership |
Joel Smith | General Counsel, Chief Compliance Officer & EVP Corporate Development | Leadership |
Amara Siva | VP, Lab Operations | Leadership |
Charles Kennedy | Board Member | Board & advisors |
Richard Eglen | Board Member | Board & advisors |
James E Rothman | Board Member | Board & advisors |
Andrew Elbardissi | Board Member | Board & advisors |
Greg Lucier | Chairman | Board & advisors |
Kim Kamdar | Board Member | Board & advisors |
Complete people profiles for Epic Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Epic Sciences
3 dated milestones of Epic Sciences across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Epic Sciences is founded.
- Funding First funding round of $2.5M.
- Funding Latest funding round, Series G, of $24.0M.
Competitors of Epic Sciences
Epic Sciences has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Foundation Medicine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. |
Detailed competitors of Epic Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Epic Sciences
The website of Epic Sciences (epicsciences.com) receives about 35.3K visits a month and ranks #589,878 among all websites worldwide, #619 in Biotechnology and Pharmaceuticals.
- Monthly visits35.3K
▼ 42.3% vs previous month
- Unique visitors24.6K
per month
- Global rank#589,878
among all websites
- Category rank#619
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit1.8
- Average visit16 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with Epic Sciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| syndax.com | 100% | 12.2K | #1,539,978 | View details | |
| ventana.com | 91% | #13,526,773 | View details | ||
| pcf.org | 54% | 64.7K | #581,321 | View details | |
| genomeweb.com | 53% | 116.4K | #371,609 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Epic Sciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Epic Sciences
Complete news archive for Epic Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epic Sciences
Epic Sciences was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Epic Sciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Epic Sciences is a funded company, having raised a total of $204.5M across 7 funding rounds to date. The company's 1st funding round was a Series A of $2.5M, raised on Jun 2009.
Epic Sciences has 98 employees.
Provider of non-invasive tests for the detection of circulating tumor cells. The proprietary platform uses specialized assays and advanced digital pathology algorithms to identify circulating tumor cells from whole blood. The flagship product is Epic AR-V7 which detects the presence of AR-V7 biomarker in whole blood and associates it with the response rate for treatment with Zytiga and Xtandi. The first proposed application is metastatic castration-resistant prostate cancer.
Epic Sciences's top competitors include Guardant Health, GRAIL and Foundation Medicine.
Epic Sciences offers AR-V7 Test and Biopharma Solutions.
Epic Sciences has 18 investors. Key investors include LabCorp, Roche, ARE, Varian, and Arsenal Capital Partners.
Epic Sciences operates through Epic Sciences, Inc..